Products
Ordesekimab Biosimilar Monoclonal Antibody (IL-15) for Research
Pre-Made Ordesekimab biosimilar, Whole Mab: Anti-IL15 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-410-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ordesekimab biosimilar, Whole Mab: Anti-IL15 therapeutic antibody |
| INN Name | Ordesekimab |
| Target | IL15 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Genmab;Immunex Corporation;Amgen;Cellimmune |
| Conditions Approved | na |
| Conditions Active | Psoriasis;Inflammatory arthritis diseases;Celiac disease |
| Conditions Discontinued | na |
| Development Tech | na |
About target - IL15
1. Protein Interleukin-15
2. Gene IL15
3. Organism Homo sapiens (Human)
Function
Cytokine that stimulates the proliferation of T-lymphocytes (PubMed:8178155).
Stimulation by IL15 requires interaction of IL15 with components of the IL2 receptor, including IL2RB and probably IL2RG but not IL2RA (PubMed:8178155).
In neutrophils, stimulates phagocytosis probably by signaling through the IL15 receptor, composed of the subunits IL15RA, IL2RB and IL2RG, which results in kinase SYK activation (PubMed:15123770).
